Tag Archives: HQY

Top 5 Casino Stocks To Invest In Right Now

Billionaire investor Carl Icahn is all but exiting the casino industry, selling his stake in Tropicana Entertainment for $1.85 billion. But maybe Eldorado Resorts (NASDAQ:ERI)– which will operate the properties bought by real estate investment trust (REIT)Gaming & Leisure Properties (NASDAQ:GLPI)– shouldn’t be going all in.

Eldorado may be piling too much onto its plate, having also purchased Isle of Capri Casinos last year for $1.75 billion and making a small tuck-in acquisition of an Illinois casino at the same time as the Tropicana deal.

Image source: Getty Images.

A rise to prominence out of bankruptcy

Icahn Enterprises (NASDAQ:IEP) bought Tropicana in 2008 during the collapse of the financial markets. In 2010, Tropicana emerged from bankruptcy protection under a $200 million deal brokered by Icahn, which gave him control of eight casinos in Indiana, Louisiana, Mississippi, Nevada, Missouri, New Jersey, and Aruba. The Aruba resortis not included in the current deal, but will be sold at a later date.

Top 5 Casino Stocks To Invest In Right Now: HealthEquity, Inc.(HQY)

Advisors’ Opinion:

  • [By Max Byerly]

    Healthequity Inc (NASDAQ:HQY) – Research analysts at Barrington Research issued their Q2 2019 EPS estimates for shares of Healthequity in a report issued on Tuesday, June 5th. Barrington Research analyst A. Paris. Jr expects that the company will post earnings per share of $0.20 for the quarter. Barrington Research currently has a “Outperform” rating and a $85.00 target price on the stock. Barrington Research also issued estimates for Healthequity’s FY2019 earnings at $0.70 EPS.

  • [By Brian Feroldi]

    For example, I used finvizin the recent past to find a dynamic growth company called HealthEquity (NASDAQ:HQY). I quickly learned that HealthEquity’s revenue and earnings have compounded at 38% and 57%, respectively, over the last five years. Those numbers convinced me to dig deeper and I soon became so excited about the company’s prospects that I purchased shares for myself right away.

  • [By Benzinga News Desk]

    A distillery in a small Spanish town has claimed it invented the original Coca-Cola (NYSE: KO) recipe and now wants recognition: Link

    ECONOMIC DATA
    Initial Jobless Claims For Week Ended May 25 221K vs 225K Economist Estimate, Down From 234K In Prior Week
    Personal Income Apr. Up 0.3%, Personal Spending Up 0.6%
    The Chicago PMI for May is schedule for release at 9:45 a.m. ET.
    The pending home sales index for April will be released at 10:00 a.m. ET.
    The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
    The Energy Information Administration’s weekly report on petroleum inventories will be released at 11:00 a.m. ET.
    Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 12:30 p.m. ET.
    Fed Governor Lael Brainard will speak at 1:00 p.m. ET.
    Data on money supply for the recent week will be released at 4:30 p.m. ET.
    Federal Reserve Bank of Dallas President Robert Kaplan is set to speak at 8:30 p.m. ET.
    ANALYST RATINGS
    Canaccord upgrades Biogen (NASDAQ: BIIB) from Hold to Buy
    Morgan Stanley upgrades Corning (NYSE: GLW) from Equal-Weight to Overweight
    Morgan Stanley downgrades Micron (NASDAQ: MU) from Overweight to Equal-Weight
    Cantor downgrades HealthEquity (NASDAQ: HQY) from Overweight to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

Top 5 Casino Stocks To Invest In Right Now: Seaspan Corporation(SSW)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Shares of Seaspan Corp (NYSE:SSW) have been on fire in 2018, rocketing 50.8% through the end of June, according to data provided by S&P Global Market Intelligence. Several factors helped drive the rebound.

  • [By ]

    Cramer was bearish on Seaspan (SSW) , Symantec (SYMC) and Hi-Crush Partners (HCLP) .

    Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

  • [By Ethan Ryder]

    Here are some of the news headlines that may have impacted Accern’s rankings:

    Get Seaspan alerts:

    Seaport Global Securities Equities Analysts Reduce Earnings Estimates for Seaspan Co. (SSW) (americanbankingnews.com) Consolidated Research: 2018 Summary Expectations for Seaspan, Canadian Imperial Bank of Commerce, B (nasdaq.com) Consolidated Research: 2018 Summary Expectations for Seaspan, Canadian Imperial Bank of Commerce, Bank Of Montreal, Fomento Economico Mexicano S.A.B. de C.V, Xcerra, and Arch Capital Group Fundamental Analysis, Key Performance Indications (finance.yahoo.com) Seaspan (SSW) Says Fairfax Financial Invested Additional $500 Million (streetinsider.com) Fairfax To Raise Total Investment In Seaspan To $1 Bln – Quick Facts (nasdaq.com)

    Several equities research analysts have commented on the company. Bank of America upgraded Seaspan from an “underperform” rating to a “buy” rating in a research note on Thursday, May 3rd. Citigroup boosted their target price on Seaspan from $7.00 to $8.50 and gave the company a “neutral” rating in a research note on Friday, May 4th. Deutsche Bank upgraded Seaspan from a “hold” rating to a “buy” rating and boosted their target price for the company from $7.00 to $13.00 in a research note on Thursday, April 19th. Morgan Stanley boosted their target price on Seaspan from $5.50 to $6.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. Finally, Zacks Investment Research upgraded Seaspan from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 20th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $9.40.

  • [By Joseph Griffin]

    News headlines about SEASPAN Corp/SH SH (NYSE:SSW) have trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SEASPAN Corp/SH SH earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned media headlines about the shipping company an impact score of 46.6781458026115 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

  • [By Maxx Chatsko]

    Rental rates aren’t the only thing gaining momentum. Several companies are demonstrably stronger today, including containership leader Seaspan (NYSE:SSW). The investor favorite has made moves to strengthen its long-term prospects just in time to capitalize on rebounding global demand for shipping vessels of nearly every size. Throw in the purchase of a Chinese joint venture, which injected youthful vessels and new contracts into the business, and a $500 million investment from a major shareholder, and it’s easy to see why shares are up 80% in the last year alone.

Top 5 Casino Stocks To Invest In Right Now: Ossen Innovation Co., Ltd.(OSN)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares jumped 29.86 percent to close at $2.87 on Friday.
    Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares gained 28.87 percent to close at $8.75 after reporting upbeat Q1 earnings.
    Mexco Energy Corporation (NYSE: MXC) gained 27.02 percent to close at $5.4744.
    Carbon Black, Inc. (NASDAQ: CBLK) climbed 26 percent to close at $23.94. Carbon Black priced its IPO at $19 per share.
    Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) rose 25.64 percent to close at $42.44 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban.
    Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.19 percent to close at $8.50 after reporting Q2 results.
    California Resources Corporation (NYSE: CRC) shares gained 22.45 percent to close at $31.58 following upbeat Q1 earnings.
    Atomera Incorporated (NASDAQ: ATOM) gained 22.31 percent to close at $6.25 after reporting Q1 results.
    Medifast, Inc. (NYSE: MED) shares jumped 22.27 percent to close at $121.46 after the company reported strong Q1 results and raised its FY18 guidance.
    Jerash Holdings (US), Inc. (NASDAQ: JRSH) gained 20.86 percent to close at $8.46.
    Pandora Media, Inc. (NYSE: P) rose 19.83 percent to close at $6.89 after reporting strong quarterly results.
    Shake Shack Inc (NYSE: SHAK) rose 18.01 percent to close at $55.95 on Friday after the company reported upbeat results for its first quarter and raised its FY18 guidance.
    Super Micro Computer, Inc. (NASDAQ: SMCI) rose 17.73 percent to close at $21.25 after reporting strong preliminary results for the third quarter.
    Schmitt Industries, Inc. (NASDAQ: SMIT) rose 17.41 percent to close at $2.36.
    Titan International, Inc. (NYSE: TWI) shares gained 16.78 percent to close at $12.25 following Q1 earnings.
    Integer Holdings Corporation (NYSE: ITGR) shares rose 14.23 percent to close at $63.40 following Q1 result
  • [By Stephan Byrd]

    News articles about Ossen Innovation (NASDAQ:OSN) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ossen Innovation earned a news impact score of 0.21 on Accern’s scale. Accern also assigned news articles about the construction company an impact score of 45.9401388856467 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Top 5 Casino Stocks To Invest In Right Now: Caleres, Inc.(CAL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Caleres (CAL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    American International Group Inc. decreased its holdings in Caleres Inc (NYSE:CAL) by 19.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,909 shares of the textile maker’s stock after selling 6,663 shares during the quarter. American International Group Inc.’s holdings in Caleres were worth $904,000 at the end of the most recent reporting period.

Top 5 Casino Stocks To Invest In Right Now: Insys Therapeutics, Inc.(INSY)

Advisors’ Opinion:

  • [By Brian Orelli]

    Shares of Insys Therapeutics(NASDAQ:INSY) rose 11% in June, according to data provided byS&P Global Market Intelligence. While the biotech is most famous for its opioid painkiller Subsys as well as Syndros, which is based on a compound in marijuana, it was clinical trial datafrom a new product that has investors excited.

  • [By Casey Wilson]

    Others, like cannabis biotech firm Insys Therapeutics Inc. (Nasdaq: INSY), are direct plays in marijuana businesses that offer investors the opportunity for incredibly fast gains.

  • [By Sean Williams]

    Yet in spite of this momentum, drug developer Insys Therapeutics (NASDAQ:INSY) has been an absolute train wreck. Insys offers a broad spectrum of therapies in its product portfolio and pipeline, but it gets its association with “marijuana stocks” through its Food and Drug Administration (FDA) approval of Syndros, a liquid dronabinol solution — i.e., a synthetic form of tetrahydrocannabinol (THC), the psychoactive component of the cannabis plant — designed to treat chemotherapy-induced nausea and vomiting, as well as anorexia associated with AIDS. It also has other cannabidiol-based products in development in its pipeline.

  • [By Joseph Griffin]

    These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

    Get Insys Therapeutics alerts:

    Chemotherapy Induced Nausea and Vomiting – Pipeline Insight, 2018 Market Report; Launched via MarketResearchReports.com (digitaljournal.com) Insys Therapeutics (INSY) Presents At Jefferies 2018 Global Healthcare Conference – Slideshow (seekingalpha.com) Insys Therapeutics (INSY) Expected to Announce Quarterly Sales of $27.32 Million (americanbankingnews.com) INSYS Therapeutics, Inc. (INSY)- Price to Book (P/B) Ratio in the Limelight (nasdaqfortune.com) INSYS Therapeutics to Present at Jefferies Global Healthcare Conference (globenewswire.com)

    Shares of NASDAQ:INSY traded up $0.09 during mid-day trading on Monday, reaching $6.96. The stock had a trading volume of 19,958 shares, compared to its average volume of 602,835. The company has a market capitalization of $507.07 million, a P/E ratio of -14.20 and a beta of 1.09. Insys Therapeutics has a 1 year low of $4.10 and a 1 year high of $14.00.

  • [By Keith Speights]

    The Intelligent Investor was written in 1949, but it’s still as relevant nearly 70 years later as it was back then. Benjamin Graham was right about how crazy the market can be at times. I think the experiences of two very different biotech stocks this week — Celgene (NASDAQ:CELG) and Insys Therapeutics (NASDAQ:INSY)– prove the point.

Top Medical Stocks To Watch Right Now

By Paul Lebo, CFA and Greg Wilkins

Athersys Inc.

Athersys Incorporated (Ticker: ATHX) is a biotechnology company that is focused primarily in the field of regenerative medicine and is committed to the discovery and development of best-in-class therapies designed to extend and enhance the quality of human life. ATHX has established a portfolio of therapeutic product development programs to address significant unmet medical needs in multiple disease areas. Their lead project that has the most potential is MultiStem cell therapy, a patented and proprietary allogeneic stem cell product, with several clinical stage programs. ATHXs current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients. These represent major areas of clinical need, as well as substantial commercial opportunities and ATHX is pursuing opportunities in several potential multi-billion dollar markets.

Top Medical Stocks To Watch Right Now: MicroStrategy Incorporated(MSTR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on MicroStrategy (MSTR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Medical Stocks To Watch Right Now: Euronav NV(EURN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Teradyne, Inc. (NYSE: TER) fell 10.8 percent to $37.02 in pre-market trading after the company issued downbeat Q2 guidance.
    Edwards Lifesciences Corporation (NYSE: EW) fell 9.2 percent to $122.29 in pre-market trading. Edwards Lifesciences reported better-than-expected results for its first quarter, but issued weak earnings guidance for the second quarter.
    New Gold Inc. (NYSE: NGD) fell 8.8 percent to $2.30 in pre-market trading after rising 4.13 percent on Tuesday.
    Gold Fields Limited (ADR) (NYSE: GFI) fell 8.6 percent to $3.61 in pre-market trading.
    Natus Medical Incorporated (NASDAQ: BABY) fell 8.2 percent to $32.95 in pre-market trading after the company issued weak forecast for the second quarter.
    Atossa Genetics Inc. (NASDAQ: ATOS) shares fell 7.9 percent to $3.50 in pre-market trading after climbing 27.09 percent on Tuesday.
    Bright Scholar Education Holdings Limited (NYSE: BEDU) shares fell 6.7 percent to $13.58 in pre-market trading after reporting Q1 results.
    Sangamo Therapeutics Inc (NASDAQ: SGMO) fell 5.9 percent to $16.75 in pre-market trading following announcement of a $200 million common stock offering.
    Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) shares fell 5.7 percent to $3.29 in pre-market trading after declining 3.32 percent on Tuesday.
    Euronav NV (NYSE: EURN) fell 4.8 percent to $8.40 in pre-market trading.
    Limelight Networks, Inc. (NASDAQ: LLNW) shares fell 4.3 percent to $4.69 in pre-market trading.
    Gaming and Leisure Properties Inc (NASDAQ: GLPI) shares fell 4.1 percent to $32.92 in pre-market trading after the company issued downbeat quarterly results and reported the retirement of CFO William Clifford

  • [By Logan Wallace]

    Seanergy Maritime (NASDAQ: SHIP) and Euronav (NYSE:EURN) are both small-cap transportation companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Top Medical Stocks To Watch Right Now: HealthEquity, Inc.(HQY)

Advisors’ Opinion:

  • [By Max Byerly]

    Healthequity Inc (NASDAQ:HQY) – Research analysts at Barrington Research issued their Q2 2019 EPS estimates for shares of Healthequity in a report issued on Tuesday, June 5th. Barrington Research analyst A. Paris. Jr expects that the company will post earnings per share of $0.20 for the quarter. Barrington Research currently has a “Outperform” rating and a $85.00 target price on the stock. Barrington Research also issued estimates for Healthequity’s FY2019 earnings at $0.70 EPS.

  • [By Motley Fool Staff]

    HealthEquity, Inc. (NASDAQ:HQY)Q1 2019 Earnings Conference CallJune 4, 2018, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    With this in mind, we asked three Motley Fool investors to name one healthcare stock that’s tops on their list for the month of June. These three mid-cap stocks made the cut: royalty drug company Innoviva (NASDAQ:INVA), mental illness treatment center operator Acadia Healthcare (NASDAQ:ACHC), and health savings account provider HealthEquity (NASDAQ:HQY).

Top Medical Stocks To Watch Right Now: Allied Motion Technologies, Inc.(AMOT)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Allied Motion Technologies (AMOT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Allied Motion Technologies, Inc. (NASDAQ:AMOT) shares reached a new 52-week high during trading on Thursday . The stock traded as high as $50.26 and last traded at $50.29, with a volume of 3496 shares traded. The stock had previously closed at $48.18.

Top Medical Stocks To Watch Right Now: Gladstone Commercial Corporation(GOOD)

Advisors’ Opinion:

  • [By Shane Hupp]

    Goodomy (GOOD) is a PoW/PoS token that uses the Scrypt hashing algorithm. Its launch date was June 21st, 2017. Goodomy’s total supply is 888,000,000 tokens and its circulating supply is 620,508,777 tokens. Goodomy’s official Twitter account is @GoodKarmaCoin and its Facebook page is accessible here. Goodomy’s official website is goodomy.com.

  • [By Max Byerly]

    Goodomy (GOOD) is a PoW/PoS token that uses the Scrypt hashing algorithm. Its genesis date was June 21st, 2017. Goodomy’s total supply is 888,000,000 tokens and its circulating supply is 620,508,777 tokens. Goodomy’s official Twitter account is @GoodKarmaCoin and its Facebook page is accessible here. Goodomy’s official website is goodomy.com.

Top Medical Stocks To Watch Right Now: Shore Bancshares Inc(SHBI)

Advisors’ Opinion:

  • [By Joseph Griffin]

    LSV Asset Management increased its stake in Shore Bancshares Inc (NASDAQ:SHBI) by 134.4% during the 1st quarter, Holdings Channel reports. The firm owned 157,489 shares of the bank’s stock after acquiring an additional 90,289 shares during the period. LSV Asset Management’s holdings in Shore Bancshares were worth $2,970,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Shane Hupp]

    Press coverage about Shore Bancshares (NASDAQ:SHBI) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Shore Bancshares earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news headlines about the bank an impact score of 46.3784121307224 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

  • [By Joseph Griffin]

    Media coverage about Shore Bancshares (NASDAQ:SHBI) has trended somewhat positive on Sunday, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Shore Bancshares earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the bank an impact score of 47.376414932679 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Top 5 Undervalued Stocks For 2019

Warren Buffett’s the most famous buy-and-hold investor on the planet, so if his company,Berkshire Hathaway(NYSE:BRK-B)(NYSE:BRK-A), is selling a stock in its portfolio, you might want to consider selling it, too.

Fortunately, Berkshire Hathaway reveals which stocks the Oracle of Omaha is selling in itsquarterly 13F filing with the Securities and Exchange Commission. The company’s latest filing shows he sold shares in Verisk Analytics, Inc.(NASDAQ:VRSK), IBM (NYSE:IBM), and Phillips 66 (NYSE:PSX). Is it time for these stocks to exit your portfolio, too?

A long relationship ending?

When Verisk went public in 2009, Warren Buffett was the only owner not to sell any shares. Clearly, he believed that the long-term opportunity associated with crunching actuarial data for insurers was undervalued in the IPO, but he might not think that anymore.

Image source: The Motley Fool.

Top 5 Undervalued Stocks For 2019: Deluxe Corporation(DLX)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Deluxe Co. (NYSE:DLX) CEO Lee J. Schram sold 6,309 shares of the company’s stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $68.07, for a total transaction of $429,453.63. Following the completion of the sale, the chief executive officer now owns 268,181 shares in the company, valued at approximately $18,255,080.67. The sale was disclosed in a filing with the SEC, which is accessible through this link.

  • [By Shane Hupp]

    Deluxe Co. (NYSE:DLX) CEO Lee J. Schram sold 691 shares of the firm’s stock in a transaction dated Friday, June 15th. The shares were sold at an average price of $68.12, for a total value of $47,070.92. Following the sale, the chief executive officer now directly owns 268,181 shares in the company, valued at approximately $18,268,489.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

  • [By Logan Wallace]

    Shares of Deluxe Co. (NYSE:DLX) hit a new 52-week high and low during trading on Wednesday . The company traded as low as $66.95 and last traded at $66.64, with a volume of 9122 shares changing hands. The stock had previously closed at $67.67.

  • [By Joseph Griffin]

    Skyline Asset Management LP bought a new position in shares of Deluxe Co. (NYSE:DLX) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 242,100 shares of the business services provider’s stock, valued at approximately $17,918,000. Skyline Asset Management LP owned approximately 0.51% of Deluxe as of its most recent SEC filing.

Top 5 Undervalued Stocks For 2019: HealthEquity, Inc.(HQY)

Advisors’ Opinion:

  • [By Max Byerly]

    Healthequity Inc (NASDAQ:HQY) – Research analysts at Barrington Research issued their Q2 2019 EPS estimates for shares of Healthequity in a report issued on Tuesday, June 5th. Barrington Research analyst A. Paris. Jr expects that the company will post earnings per share of $0.20 for the quarter. Barrington Research currently has a “Outperform” rating and a $85.00 target price on the stock. Barrington Research also issued estimates for Healthequity’s FY2019 earnings at $0.70 EPS.

  • [By Brian Feroldi]

    For example, I used finvizin the recent past to find a dynamic growth company called HealthEquity (NASDAQ:HQY). I quickly learned that HealthEquity’s revenue and earnings have compounded at 38% and 57%, respectively, over the last five years. Those numbers convinced me to dig deeper and I soon became so excited about the company’s prospects that I purchased shares for myself right away.

  • [By Max Byerly]

    Here are some of the news headlines that may have impacted Accern’s analysis:

    Get Healthequity alerts:

    HealthEquity Inc. (HQY) VP Darcy G. Mott Cut 10000 Shares (bharatapress.com) Investors Love This Stock?: HealthEquity, Inc. (HQY) (bitcoinpriceupdate.review) Insider Selling: Healthequity Inc (HQY) Director Sells 15,000 Shares of Stock (americanbankingnews.com) Notable ETF Inflow Detected – IJT, STMP, HQY, TREX (nasdaq.com) You Need to Watch this stock? HealthEquity, Inc. (HQY) (connectinginvestor.com)

    Several brokerages have issued reports on HQY. Barrington Research boosted their price target on shares of Healthequity to $85.00 and gave the company an “outperform” rating in a report on Tuesday, June 5th. They noted that the move was a valuation call. Oppenheimer boosted their price target on shares of Healthequity from $68.00 to $85.00 and gave the company an “outperform” rating in a report on Tuesday, June 5th. Robert W. Baird boosted their price target on shares of Healthequity from $61.00 to $77.00 and gave the company a “neutral” rating in a report on Tuesday, June 5th. SunTrust Banks boosted their price target on shares of Healthequity from $70.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, June 5th. Finally, KeyCorp boosted their price target on shares of Healthequity from $72.00 to $82.00 and gave the company an “overweight” rating in a report on Tuesday, June 5th. Three investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $77.00.

  • [By Benzinga News Desk]

    A distillery in a small Spanish town has claimed it invented the original Coca-Cola (NYSE: KO) recipe and now wants recognition: Link

    ECONOMIC DATA
    Initial Jobless Claims For Week Ended May 25 221K vs 225K Economist Estimate, Down From 234K In Prior Week
    Personal Income Apr. Up 0.3%, Personal Spending Up 0.6%
    The Chicago PMI for May is schedule for release at 9:45 a.m. ET.
    The pending home sales index for April will be released at 10:00 a.m. ET.
    The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
    The Energy Information Administration’s weekly report on petroleum inventories will be released at 11:00 a.m. ET.
    Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 12:30 p.m. ET.
    Fed Governor Lael Brainard will speak at 1:00 p.m. ET.
    Data on money supply for the recent week will be released at 4:30 p.m. ET.
    Federal Reserve Bank of Dallas President Robert Kaplan is set to speak at 8:30 p.m. ET.
    ANALYST RATINGS
    Canaccord upgrades Biogen (NASDAQ: BIIB) from Hold to Buy
    Morgan Stanley upgrades Corning (NYSE: GLW) from Equal-Weight to Overweight
    Morgan Stanley downgrades Micron (NASDAQ: MU) from Overweight to Equal-Weight
    Cantor downgrades HealthEquity (NASDAQ: HQY) from Overweight to Neutral

    This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

  • [By Brian Feroldi]

    So where am I going to invest my capital? While I’m still refining my list, here are seven stocks that I currently own that I’m strongly considering adding to:

    Hubspot (NYSE: HUBS) — A software-as-a-service provider that is pioneering the shift toward “inbound” marketing. HealthEquity (NASDAQ: HQY) — A fast-growing company focused on Health Savings Accounts that boasts three sources of recurring revenue. Axon Enterprise (NASDAQ: AAXN) — The leading provider ofTaser stun guns, law enforcement body cameras, and evidence-management software. Paycom Software (NYSE: PAYC) — A founder-ledpayroll-processor company that is gobbling up market share. Adobe Systems (NASDAQ: ADBE)– The company’s push to the cloud is drivingdouble-digitgains in revenue and profits. AppFolio (NASDAQ: APPF) — Asoftware-as-a-service provider focused on servicing business owners in severalniche markets. BlackLine (NASDAQ: BL) — A software company that is attempting to bring the accounting process into the 21st century.

    All seven of these businesses are poised to deliver double-digit organic revenue and profit growth over the next five years. That’s a prospect I find quite enticing, and I think the odds are very favorable that they’ll outperform Apple as a group from here.

  • [By Motley Fool Staff]

    HealthEquity, Inc. (NASDAQ:HQY)Q1 2019 Earnings Conference CallJune 4, 2018, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 5 Undervalued Stocks For 2019: Tyson Foods Inc.(TSN)

Advisors’ Opinion:

  • [By ]

    But what investors are overlooking are the fundamental risks to this logic. Corporate earnings are the lifeblood of the market, keep in mind. Higher oil prices have already translated into higher gas prices, which is a key risk to automakers such as Ford (F) and General Motors (GM) that have pivoted big-time to producing SUVs and trucks. Higher oil prices have already taken a toll on earnings for packaged food giants like Proctor & Gamble (PG) and Tyson Foods (TSN) . Now, each are staring at consumer price increases because it costs more to deliver their products to stores.

  • [By Shane Hupp]

    HL Financial Services LLC purchased a new position in shares of Tyson Foods (NYSE:TSN) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 61,568 shares of the company’s stock, valued at approximately $4,506,000.

  • [By Logan Wallace]

    Franklin Resources Inc. cut its holdings in shares of Tyson Foods, Inc. (NYSE:TSN) by 88.7% during the first quarter, HoldingsChannel.com reports. The firm owned 58,511 shares of the company’s stock after selling 460,578 shares during the quarter. Franklin Resources Inc.’s holdings in Tyson Foods were worth $4,283,000 at the end of the most recent quarter.

  • [By Shane Hupp]

    Sanford C. Bernstein started coverage on shares of Tyson Foods (NYSE:TSN) in a research report report published on Thursday, MarketBeat Ratings reports. The brokerage issued an outperform rating on the stock.

  • [By Stephan Byrd]

    Systematic Financial Management LP boosted its position in Tyson Foods, Inc. (NYSE:TSN) by 16.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 115,734 shares of the company’s stock after acquiring an additional 16,022 shares during the quarter. Systematic Financial Management LP’s holdings in Tyson Foods were worth $8,471,000 at the end of the most recent reporting period.

Top 5 Undervalued Stocks For 2019: CA Inc.(CA)

Advisors’ Opinion:

  • [By Shane Hupp]

    CA Technologies (NASDAQ:CA) issued an update on its FY19 earnings guidance on Tuesday morning. The company provided EPS guidance of $2.75-$2.81 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.74. The company issued revenue guidance of $4.25-$4.29 billion, compared to the consensus revenue estimate of $4.31 billion.

  • [By Joseph Griffin]

    CA Technologies (NASDAQ:CA) – Equities researchers at Oppenheimer issued their Q1 2019 earnings estimates for CA Technologies in a research note issued to investors on Wednesday, May 9th. Oppenheimer analyst S. Eyal expects that the technology company will earn $0.62 per share for the quarter. Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for CA Technologies’ Q2 2019 earnings at $0.66 EPS, Q3 2019 earnings at $0.68 EPS, Q4 2019 earnings at $0.62 EPS and FY2020 earnings at $2.68 EPS.

  • [By Anders Bylund]

    When an executive order from the Trump administration shut down Broadcom’s (NASDAQ:AVGO) attempt to buy chip-making peer Qualcomm (NASDAQ:QCOM), the company wasted no time finding other targets for its buyout ambitions. Just four months later, Broadcom is acquiring business software veteran CA Inc. (NASDAQ:CA) in an $18.9 billion all-cash deal.That’s $44.50 per CA share, 19.6% above Wednesday’s closing price.

  • [By Anders Bylund]

    Enterprise software specialist CA, Inc. (NASDAQ:CA) has agreed to an $18.9 billion buyout by semiconductor giant Broadcom (NASDAQ:AVGO). CA shares rose more than 18% on the news, hovering less than 2% below the agreed acquisition price of $44.50 per share. Broadcom investors went in the opposite direction, reducing share prices by as much as 18.9%. As of 1:40 p.m. EDT, Broadcom shares had recovered slightly to a 15.2% drop.

  • [By Jim Crumly]

    Meanwhile, Broadcom (NASDAQ:AVGO) announced plans to buyCA Technologies (NASDAQ:CA), causing their stocks to move strongly in opposite directions, and Delta Air Lines (NYSE:DAL) reported earnings growth despite a growing fuel bill.

Top 5 Undervalued Stocks For 2019: Magal Security Systems Ltd.(MAGS)

Advisors’ Opinion:

  • [By Logan Wallace]

    Media coverage about Magal Security Systems (NASDAQ:MAGS) has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Magal Security Systems earned a news impact score of 0.18 on Accern’s scale. Accern also gave news headlines about the industrial products company an impact score of 48.2585076972472 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

  • [By Lisa Levin]

    Magal Security Systems Ltd. (NASDAQ: MAGS) is expected to report earnings for its first quarter.

    Four Seasons Education (Cayman) Inc. (NASDAQ: FEDU) is projected to report quarterly earnings at $0.04 per share on revenue of $11.74 million.

Top Performing Stocks To Buy For 2017

Wynn Resorts (WYNN) soared nearly to the top of the S&P 500 today after Morgan Stanley argued that the casino stock had the potential to double.

Agence France-Presse/Getty Images

Wynn Resortsgained 4.8% to $104.30 today, while the S&P 500 finished little changed at2,373.47. At 2:45, Wynn was easily the top performing stock in the S&P 500, only to be surpassed by Citrix’s (CTXS) late day surge.

Morgan Stanley’s Thomas Allen and team explain how Wynn could double:

Our AlphaWise work on Google search data and separate analyses of market trends suggest the Street is too low on WYNN’s Macau market share gains. Our base case implies 20% upside; bull case, the stock could double.

Consensus forecasts WYNN to essentially not grow Macau market share over 4Q16, despite the Aug ’16 opening of Wynn Palace (which increased WYNN’s room capacity by 170%) and the general view that the benefit from the property has been disappointing so far. We see upside to WYNN’s market share supported by (1) analysis of Google search trends, (2) current market dynamics and WYNN actions, and (3) the performance of WYNNs first Macau property

Top Performing Stocks To Buy For 2017: New York & Company Inc.(NWY)

Advisors’ Opinion:

  • [By Monica Gerson]

    New York & Company, Inc. (NYSE: NWY) shares dropped 42 percent to $1.72 after the company reported downbeat Q1 results and issued a weak Q2 forecast.

  • [By Lisa Levin]

    Shares of New York & Company, Inc. (NYSE: NWY) got a boost, shooting up 13 percent to $2.31 as the company posted upbeat quarterly results.

    The GEO Group Inc (NYSE: GEO) shares were also up, gaining 19 percent to $23.27. Following Thursday’s Department of Justice news regarding privately-managed prisons, GEO Group dropped on Thursday, but rebounded Friday after issuing a response to the DoJ.

Top Performing Stocks To Buy For 2017: Barclays PLC(BCS)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Barclays PLC (NYSE: BCS) was raised to Overweight from Equal Weight at Morgan Stanley. Its American depositary sharesclosed up 2.6% at $11.36 on Thursday and were indicated up 1.2% at $11.50 on Friday. The52-week range is $6.76 to $12.05.

  • [By WWW.THESTREET.COM]

    Banco Santander (SAN) : “I prefer Barclays (BCS) , but let’s wait and see what the other banks have to say”

    ProLogis (PLD) : “I am not a fan of that group right now, but that one is best of breed.”

Top Performing Stocks To Buy For 2017: HealthEquity, Inc.(HQY)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

Top Performing Stocks To Buy For 2017: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha) Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha) Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period. Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share. Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement. Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share. Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76. QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share. Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering. Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

small investments

I have been following Gilead Sciences (NASDAQ:GILD) for a while. Piper Jaffray’s Healthcare Conference gave me the chance to reassess GILD’s attractiveness. I would like to share a few thoughts about Gilead’s future prospects.

Click to enlarge

Pipeline developments and growth – Waiting for NASH?

When Piper Jaffray’s analyst Joshua Schimmer asked a question about how management is trying to improve growth prospects for the company, CEO John Milligan gave a broad answer. I would like to draw attention to a few points.

Talking about Memolitinib, Milligan said:

small investments: LKQ Corporation(LKQ)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday's regular session.

small investments: HealthEquity, Inc.(HQY)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

small investments: Duluth Holdings Inc.(DLTH)

Advisors’ Opinion:

  • [By Lisa Levin]

    Duluth Holdings Inc (NASDAQ: DLTH) shares were also up, gaining 23 percent to $21.94 as the company reported upbeat results for its fourth quarter on Thursday.

  • [By Monica Gerson]

    Duluth Holdings Inc (NASDAQ: DLTH) is projected to post its quarterly earnings at $0.28 per share on revenue of $133.21 million.

    DBV Technologies SA ADR (NASDAQ: DBVT) is expected to post a quarterly loss at $0.60 per share.

  • [By Monica Gerson] Related DLTH After-Hours Recap: CarMax, Wynn, Relypsa, ConAgra, Ruby Tuesday & More Earnings Scheduled For April 7, 2016 Duluth Holdings' (DLTH) CEO Stephanie Pugliese on Q4 2015 Results – Earnings Call Transcript (Seeking Alpha) Related GPS After-Hours Recap: CarMax, Wynn, Relypsa, ConAgra, Ruby Tuesday & More Gap Comps Down 6% In March; Shares Plunge Difficult March Comparisons Were Too High For Retailers To Beat (Seeking Alpha)

    Some of the stocks that may grab investor focus today are:

  • [By Jason Hall, Travis Hoium, and Brian Feroldi]

    In our ongoing search for just such quality growth stocks, we asked three of our contributors to pick out ones they think have high growth potential from here, and tell us why. They gave us a unique retailer that’s carving out a huge following in Duluth Holdings(NASDAQ:DLTH), a recovering fast-casual dining darling inChipotle Mexican Grill (NYSE:CMG), and a gaming and resorts giant,Wynn Resorts (NASDAQ:WYNN).

small investments: Roper Technologies, Inc.(ROP)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Flexing the barbell strategy to balance Safe Havens with more cyclical exposures. In our view, industrials investors should be positioning their portfolio with a barbell strategy, with half of the exposure in Safe Havens like General Electric, Xylem (XYL), Danaher, Honeywell International, Roper Technologies (ROP), and AMETEK (AME), and the other half selectively in the cyclical names that are better positioned today, such as Pentair, HD Supply Holdings (HDS),Actuant (ATU), Atkore International Group (ATKR), Ingersoll-Rand, and Eaton (ETN). We still believe risk-reward is mostly balanced and that the macro will remain choppy into 2017, supporting a positioning in the defensive names. But if investor sentiment improves on not-worse news and earnings results, the more cyclical names could fare better.

  • [By Monica Gerson]

    Analysts are expecting Roper Technologies Inc (NYSE: ROP) to have earned $1.46 per share on revenue of $895.87 million in the latest quarter. Roper Technologies shares declined 0.05 percent to close at $178.63 on Friday.

  • [By Monica Gerson]

    Roper Technologies Inc (NYSE: ROP) is projected to report its quarterly earnings at $1.46 per share on revenue of $895.87 million.

    Express Scripts Holding Company (NASDAQ: ESRX) is expected to post its quarterly earnings at $1.22 per share on revenue of $25.20 billion.

  • [By Ben Levisohn]

    Aside from Outperform-rated Roper Technologies (ROP) SaaS platforms, which account for over +50% of earnings today, GEs Digital business strategy is the most ambitious ramp within the industrials sector. GE has made a bold bet on its game-changing Predix operating system for the Industrial IoT, which was launched in Feb-2016